Viral Vectors and Plasmid DNA Manufacturing Market Size was valued at USD 0.3 billion in 2022 and is projected to grow from USD 0.35 Billion in 2023 to USD 1.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.1% during the forecast period (2023 - 2032).
The Viral Vectors and Plasmid DNA Manufacturing Market witness robust growth, driven by expanding applications in gene therapy, vaccine development, and biopharmaceutical production. Demand surges as gene-based therapies gain traction in treating genetic disorders, cancer, and infectious diseases. Increasing R&D investments, technological advancements, and favorable regulatory landscapes bolster market expansion. Viral vectors, including lentivirus, adenovirus, and adeno-associated virus (AAV), alongside plasmid DNA, serve as vital tools in genetic engineering. The market experiences intensifying competition among key players focusing on scalability, safety, and efficiency of production processes. Continuous innovation and strategic collaborations propel the sector forward amid evolving healthcare demands.
The Viral Vectors and Plasmid DNA Manufacturing Market is witnessing unprecedented growth, fueled by advancements in viral gene therapy and vector purification techniques. As the demand for innovative gene therapies surges, so does the need for efficient manufacturing processes to produce viral vectors and plasmid DNA, crucial components in gene therapy treatments.
Viral gene therapy holds immense promise for treating a wide array of genetic disorders and diseases by delivering therapeutic genes into target cells using viral vectors. However, ensuring the safety and efficacy of these therapies requires high-quality vectors and plasmid DNA. Vector purification plays a pivotal role in this process, enabling the removal of impurities and ensuring the vectors meet stringent quality standards.
Manufacturers in this market are investing heavily in research and development to enhance vector purification methods, streamline manufacturing processes, and scale up production to meet growing demand. Moreover, advancements in biotechnology and genetic engineering are driving innovation, leading to the development of more efficient viral vectors and plasmid DNA constructs.
The Viral Vectors and Plasmid DNA Manufacturing Market is characterized by intense competition and collaboration among key players to expand their product portfolios, improve manufacturing capabilities, and meet evolving regulatory requirements. As the field of gene therapy continues to evolve, the market for viral vectors and plasmid DNA manufacturing is poised for significant growth, offering new hope for patients suffering from genetic disorders and chronic diseases.
Regional Analysis
Based on region, North America is expected to dominate the global viral vector and plasmid DNA manufacturing market in 2020. Factors such as the presence of a largenumber of centers and institutes engaged in the R&D of advanced therapies and key players in this region involved in new product launches, expansion, acquisition,and strategic collaborations are driving the market growth. For instance, In March 2021, ABECMA (idecabtagenevicleucel), a lentivirus-based gene therapy, received the US FDA approvalto treat R/R multiple myeloma.
Europe is expected to hold the second-largest position in the global viral vector and plasmid DNA manufacturing market in 2021. Key factors attributing to the market growth are the increasing R&D spendings to enhance research activities in the healthcare industry. For instance, according to the data published in Eurostat in 2018, the EU spent approximately 348 USD million on Research & Development. The R&D expenditure as a percentage of GDP was 2.18% in 2018, compared to 1.87 % in 2008.
Asia-Pacific is anticipated to be the fastest-growing regional market over the assessment period due to the increasing prevalence of target disorders and healthcare needs. Furthermore, the growth of the market in the rest of the world is attributed to the rising penetration of advanced healthcare technologies in research organizations focused on viral vector and plasmid DNA manufacturing incountries such as Saudi Arabia and the UAE. Developing countries such as Argentina, Brazil, and Colombia, among others in Latin America, are also key contributors to the growth of the market.
Segmentation
The global viral vector and plasmid DNA manufacturing market has been segmented intovector type, workflow, disease type, application, and end user.
By vector type, the market is segmented into plasmid DNA, viral vector, non-viral vector. The viral vector segment represented the dominant share in 2020, owing to the rising prevalence of target diseases and disorders, the effectiveness of viral vectors in gene therapy delivery, and rising research activities focused on viral vector-based gene & cell therapies.
Based on the workflow, the market is segmented into upstream processing, downstream processing. Downstream processing dominated the market for viral vectors and plasmid DNA manufacturing in 2020. Increasing adoption of downstream processing methods to help reduce contaminants originating from host cells or culture media is driving the market growth of this segment.
On the basis of disease type, the market has been segmented into genetic disorders, cancer, infectious diseases, and others. Cancer held the largest market share in 2020 due to the increasing prevalence of cancer cases globally. Furthermore, geneticdisordersare expected to be the fastest-growing segment.
Based on application, the market is segmented into antisense & RNAi therapy, gene therapy, cell therapy, vaccinology, and research. The vaccinology segment dominated the market in 2020, owing tothe rising adoption of viral vectors in vaccine development.
By end user, pharmaceutical & biopharmaceutical companies and research institutes. Research institutes held a major share in the global viral vectors and plasmid DNA manufacturing market. The increasing number of research centers in gene and cell therapy coupled with rising research activities for viral vectors and plasmid DNA is projected to increase the demand for viral vectors in the global market.
Key Players
The global Viral Vector and Plasmid DNA Manufacturing companies are Cognate BioServices, Inc. (US), Catalent Pharma Solutions (US), Fujifilm Holdings Corporation (Japan), Johnson & Johnson (US), Sanofi Corporation (France), F. Hoffmann-LA Roche Ltd (Switzerland), 4D Molecular Therapeutics (US), Sirion Biotech GmbH (Germany), Voyager Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Gene Therapy Catapult (UK), UniQure (Netherlands), MassBiologics (US), Renova Therapeutics (US) and Shenzhen SiBionoGeneTech Co., Ltd (China).
Related Reports:
Asia-Pacific Interventional Cardiology
For More Information, Please Visit @ Market Research Future
